Description: True Blue

Description: 71431-30-6

Description: JBS True Blue

Description: Biotin-MAGE-A2 (157-166) is the N-ter biotinylated version of MAGE-A2 (157-166). Biotin-MAGE-A2 (157-166) can be used in the analysis of antigen-specific T cells. MAGE-A2 protein: MAGE-A2 (157-166) is an epitope of Melanoma Antigen Gene A2 and is one of the most Cancer-Testis Antigens (CTA) overexpressed in tumors of different histological types, such as prostate cancer. Type of MAGE-A expressed in tumors cells varies according to the type of tumor. The expression of MAGE-A2 causes the proliferation of prostate cancer cells and decreases the chemosensitivity. Applications of MAGE-A2 (157-166):MAGE-A2 (157-166) is used to stimulate specific immune response, cytotoxic T cell response and to analyze the cytokine production in PBMCs by ELISPOT assay. In transgenic mouse, it has been demonstrated that MAGE-A2 (157-166) was capable of eliciting a CTL response presented by HLA-A*02:01 molecules. MAGE-A2 (157-166) has been reported to elicit CTL that could lyse tumor cell expressing both HLA-A*02:01 and MAGE-A2 by stimulation of peripheral blood mononuclear cells (PBMCs) with MAGE-A2 (157-166).Sequence: Biotin-YLQLVFGIEV

Description: Ca channels

Description: Biotin-NY-ESO-1 (157-165) – General analog epitope of tumor cellsBiotin-NY-ESO-1 (157-165) C165V peptide is the N-ter biotinylated version of NY-ESO-1 (157-165) C165V peptide. It can be used in the analysis of antigen-specific T cells. HLA-A*02 Major Histocompatibility Complex (MHC) allele HLA-A*02 allele is expressed in class I Human MHC Leukocyte Antigens (HLA), that are cell surface receptors, presenting peptides to the immune system. If a non-self-peptide is recognized by cytotoxic T-cells in the blood, cell death will be initiated via apoptosis. NY-ESO-1 protein Peptides presented by MHC class I molecule, are usually between 7 and 11 amino acids, originating from proteins expressed by the cell. SLLMWITQV peptide differes from the New York esophageal squamous cell carcinoma 1 (NY-ESO-1 : UniProt – P78358) native SLLMWITQC peptide, whose protein is part of a well-characterized group of cancer/testis antigens (CTAs).Normally, NY-ESO-1 expression is restricted to germ cells and placental cells. However it is also expressed in 82% of neuroblastomas and 46% of melanomas, as well as in many other solid tumors and hematological malignancies. NY-ESO-1 (157-165) C165V peptide application Class I HLA molecules of the cancerous cells cited above present peptides from NY-ESO-1 protein, including SLLMWITQC, that binds the binding cleft of the HLA-A*0201 complex. NY-ESO-1 being the most immunogenic among the CTA family members, its peptides constitute attractive targets for specific immunotherapies and the stimulation of human NY-ESO-1 specific CD8+ T cells.In order to better stimulate specific cytotoxic T-cells in PBMCs and analyze by ELISPOT peptide epitope, specificity, and cytokine production, like IFN-γ, SLLMWITQV variant peptide was used, as it is known to have a higher affinity for the binding cleft of the HLA-A*0201 complex than the native peptide. Moreover, SLLMWITQV has been used with adjuvant in protein nanoparticles in order to study cell-mediated immune responses and is also used in clinical trial to study the immunological effects of vaccines containing NY-ESO-1 (157-165) C165V.SB-PEPTIDE also offers the scrambled version of NY-ESO-1 (157-165) C165V peptide, as well as NY-ESO-1 (157-165) native peptide.

Description: Biotinylated version of the Spike (S) glycoprotein which corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells.

Description: Overlaping biotin-peptide library of Spike Omicron mutant. 15 amino acids per peptide with offset 11. Each peptide is N-ter biotinylated. Purity crude. 1 peptide per well.

Description: A polyclonal antibody against INSIG1. Recognizes INSIG1 from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA

Description: Biotin-SARS-CoV-2 Spike RBD 319-335 peptide is the biotinylated version of SARS-CoV-2 Spike RBD 319-335 peptide. SARS-CoV-2 Spike RBD 319-335 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Domain (RBD). Biotin-SARS-CoV-2 Spike RBD 319-335 peptide is useful for vaccine development and for structure-activity relationship studiesSARS-CoV-2 Spike (S) glycoproteinSpike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells.With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane. SARS-CoV-2 Spike RBD: The receptor-binding domain in SARS-CoV-2 Spike protein allows binding to the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry.

Description: Biotin-SARS-CoV-2 Spike RBD 336-347 peptide is the biotinylated version of SARS-CoV-2 Spike RBD 336-347 peptide. SARS-CoV-2 Spike RBD 336-347 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Domain (RBD). Biotin-SARS-CoV-2 Spike RBD 336-347 peptide is useful for vaccine development and for structure-activity relationship studiesSARS-CoV-2 Spike (S) glycoproteinSpike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells.With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane. SARS-CoV-2 Spike RBD: The receptor-binding domain in SARS-CoV-2 Spike protein allows binding to the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry.

Description: Biotin-SARS-CoV-2 Spike RBD 348-357 peptide is the biotinylated version of SARS-CoV-2 Spike RBD 348-357 peptide. SARS-CoV-2 Spike RBD 348-357 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Domain (RBD). Biotin-SARS-CoV-2 Spike RBD 348-357 peptide is useful for vaccine development and for structure-activity relationship studiesSARS-CoV-2 Spike (S) glycoproteinSpike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells.With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane. SARS-CoV-2 Spike RBD: The receptor-binding domain in SARS-CoV-2 Spike protein allows binding to the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry.

Description: Biotin-SARS-CoV-2 Spike RBD 352-365 peptide is the biotinylated version of SARS-CoV-2 Spike RBD 352-365 peptide. SARS-CoV-2 Spike RBD 352-365 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Domain (RBD). Biotin-SARS-CoV-2 Spike RBD 352-365 peptide is useful for vaccine development and for structure-activity relationship studiesSARS-CoV-2 Spike (S) glycoproteinSpike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells.With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane. SARS-CoV-2 Spike RBD: The receptor-binding domain in SARS-CoV-2 Spike protein allows binding to the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry.

Description: Biotin-SARS-CoV-2 Spike RBD 371-394 peptide is the biotinylated version of SARS-CoV-2 Spike RBD 371-394 peptide. SARS-CoV-2 Spike RBD 371-394 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Domain (RBD). Biotin-SARS-CoV-2 Spike RBD 371-394 peptide is useful for vaccine development and for structure-activity relationship studiesSARS-CoV-2 Spike (S) glycoproteinSpike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells.With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane. SARS-CoV-2 Spike RBD: The receptor-binding domain in SARS-CoV-2 Spike protein allows binding to the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry.

Description: Biotin-SARS-CoV-2 Spike RBD 395-430 peptide is the biotinylated version of SARS-CoV-2 Spike RBD 395-430 peptide. SARS-CoV-2 Spike RBD 395-430 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Domain (RBD). Biotin-SARS-CoV-2 Spike RBD 395-430 peptide is useful for vaccine development and for structure-activity relationship studiesSARS-CoV-2 Spike (S) glycoproteinSpike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells.With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane. SARS-CoV-2 Spike RBD: The receptor-binding domain in SARS-CoV-2 Spike protein allows binding to the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry.